Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
| Autor: | Rebeca Lozano, David Olmos, Adam Sharp, Penelope Flohr, Pasquale Rescigno, Alison Reid, Casilda Llácer, Ylenia Cendon, Teresa Garcés, Joaquim Mateo, Maria I Pacheco, Elena Castro, Isabel M. Aragón, Shahneen Sandhu, David Lorente, Pedro P. López-Casas, Christophe Massard, Diletta Bianchini, Nuria Romero-Laorden, Paz Nombela, Johann S. de Bono |
|---|---|
| Přispěvatelé: | Institut Català de la Salut, [Lozano R, Aragon IM] Genitourinary Cancer Traslational Research Group, The Institute of Biomedical Research in Málaga (IBIMA), 29010 Málaga, Spain. Spanish National Cancer Research Centre (CNIO), Prostate Cancer Clinical Research Unit, 28029 Madrid, Spain. [Lorente D] Spanish National Cancer Research Centre (CNIO), Prostate Cancer Clinical Research Unit, 28029 Madrid, Spain. Servicio de Oncología Médica, Hospital Provincial de Castellón, 12004 Castellón de la Plana, Spain. [Romero-Laorden N] Spanish National Cancer Research Centre (CNIO), Prostate Cancer Clinical Research Unit, 28029 Madrid, Spain. Hospital Universitario La Princesa, 28006 Madrid, Spain. [Nombela P] Spanish National Cancer Research Centre (CNIO), Prostate Cancer Clinical Research Unit, 28029 Madrid, Spain. [Mateo J] The Institute of Cancer Research, London SW7 3RP, UK. The Royal Marsden NHS Foundation Trust, Sutton, London SM2 5PT, UK. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Cèl·lules canceroses - Proliferació Neoplasms::Neoplastic Processes::Neoplasm Metastasis::Neoplastic Cells Circulating [DISEASES] 030232 urology & nephrology Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] Castration resistant circulating tumor cells Other subheadings::Other subheadings::/drug therapy [Other subheadings] Article 03 medical and health sciences Prostate cancer PSA 0302 clinical medicine Circulating tumor cell Metàstasi Internal medicine medicine docetaxel In patient Prospective cohort study neoplasms RC254-282 Proportional hazards model business.industry Neoplasms. Tumors. Oncology. Including cancer and carcinogens biomarkers medicine.disease Pròstata - Càncer - Tractament Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms Male::Prostatic Neoplasms::Prostatic Neoplasms Castration-Resistant [DISEASES] Pooled analysis Docetaxel neoplasias::procesos neoplásicos::metástasis neoplásica::células neoplásicas circulantes [ENFERMEDADES] metastatic castration-resistant prostate cancer 030220 oncology & carcinogenesis neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales masculinos::neoplasias de la próstata::neoplasias prostáticas resistentes a la castración [ENFERMEDADES] business medicine.drug |
| Zdroj: | Cancers r-FHPC. Repositorio Institucional de Producción Científica de la Fundación del Hospital Provincial de Castellón Banco de España Cancers, Vol 13, Iss 2334, p 2334 (2021) Volume 13 Issue 10 Scientia |
| ISSN: | 2072-6694 |
| Popis: | Circulating tumor cell (CTC) enumeration and changes following treatment have been demonstrated to be superior to PSA response in determining mCRPC outcome in patients receiving AR signaling inhibitors but not taxanes. We carried out a pooled analysis of two prospective studies in mCRPC patients treated with docetaxel. CTCs were measured at baseline and 3–6 weeks post treatment initiation. Cox regression models were constructed to compare 6-month radiographical progression-free survival (rPFS), CTCs and PSA changes predicting outcome. Among the subjects, 80 and 52 patients had evaluable baseline and post-treatment CTC counts, respectively. A significant association of higher baseline CTC count with worse overall survival (OS), PFS and time to PSA progression (TTPP) was observed. While CTC response at 3–6 weeks (CTC conversion (from ≥5 to < 5 CTCs), CTC30 (≥30% decline in CTC) or CTC0 (decline to 0 CTC)) and 6-month rPFS were significantly associated with OS (all p < 0.005), the association was not significant for PSA30 or PSA50 response. CTC and PSA response were discordant in over 50% of cases, with outcome driven by CTC response in these patients. The c-index values for OS were superior for early CTC changes compared to PSA response endpoints, and similar to 6-month rPFS. Early CTC declines were good predictors of improved outcomes in mCRPC patients treated with docetaxel in this small study, offering a superior and/or earlier estimation of docetaxel benefit in comparison to PSA or rPFS that merits further confirmation in larger studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|